<PAGE>

           UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                       Washington, D.C.  20549
                   ______________________________

                              FORM 10-Q/A  No. 1

        X    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
       ---       THE SECURITIES EXCHANGE ACT OF 1934

          For the quarterly period ended September 30, 1995
                                 OR
   ---    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                 THE SECURITIES EXCHANGE ACT OF 1934

                     Commission file number 1-483
                   ______________________________
                                  
                       MALLINCKRODT GROUP INC.
                                                                       
        (Exact name of registrant as specified in its charter)

                                                                       
              New York                          36-1263901            
   (State or other jurisdiction of           (I.R.S. Employer
    incorporation or organization)          Identification No.)

        7733 Forsyth Boulevard
          St. Louis, Missouri                   63105-1820
(Address of principal executive offices)        (Zip Code)

Registrant's telephone number, including area code: 314-854-5200
                    ______________________________

       Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90
days.  Yes X.  No  .

          Applicable Only To Issuers Involved In Bankruptcy
             Proceedings During The Preceding Five Years:
       Indicate by check mark whether the registrant has filed all
documents and reports required to be filed by Sections 12, 13 or 15(d)
of the Securities Exchange Act of 1934 subsequent to the distribution
of securities under a plan confirmed by a court.  Yes  .  No  .

               Applicable Only To Corporate Issuers:
       Indicate the number of shares outstanding of each of the
issuer's classes of common stock, as of the latest practicable date.  
76,529,742 shares excluding 10,586,547 treasury shares as of September
30, 1995.

<PAGE>
The purpose of this amendment is to amend in its entirety Part 1, 
Item 2 to the Registrant's Quarterly Report on Form 10-Q for the
quarterly period ended September 30, 1995.


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
         AND RESULTS OF OPERATIONS.

RESULTS OF OPERATIONS 

General
-------
Earnings from continuing operations for the first quarter ended
September 30, 1995 were $36 million, or 46 cents per share.  This
represents a 15 percent increase in per-share earnings from continuing 
operations compared with $31 million, or 40 cents per share, during 
the same period a year ago.  Net sales for the quarter were up 10
percent to $492 million, compared to $449 million a year earlier.  Net
earnings for the first quarter were $39 million, or 50 cents per
share, compared with $34 million, or 44 cents per share, during the
same period a year ago.  Both fiscal 1996 and fiscal 1995 first
quarter results reflect reporting of the animal feed ingredients
business as a discontinued operation, fiscal 1995 having been
restated.  

A comparison of sales and operating earnings follows:
(In millions)                                                          
                                                                    
                                                Three Months Ended
                                                   September 30,
                                                ------------------
                                                 1995        1994
                                                ------      ------
Sales
-----
  Mallinckrodt Chemical                         $ 153       $ 111
  Mallinckrodt Medical                            238         230
  Mallinckrodt Veterinary                         101         108
                                                ------      ------
                                                $ 492       $ 449
                                                ======      ======

Operating earnings
------------------
  Mallinckrodt Chemical                         $   8       $   7
  Mallinckrodt Medical                             58          51
  Mallinckrodt Veterinary                           5           4
  Corporate                                        (7)         (6)
                                                ------      ------
                                                $  64       $  56
                                                ======      ======

Business Segments
-----------------
MALLINCKRODT CHEMICAL
Net Sales                                       Three Months Ended
(In millions)                                      September 30,
                                                ------------------
                                                 1995        1994
                                                ------      ------    
Catalyst, Performance & Lab Chemicals           $  96       $  55
Pharmaceutical Specialties                         57          56
                                                ------      ------
                                                $ 153       $ 111
                                                ======      ======

Mallinckrodt Chemical, including its $7.3 million equity-investment
share of earnings from the flavors joint venture, Tastemaker, achieved
earnings of $15.5 million for the first quarter, up 22 percent over
the prior year's $12.7 million.  Net sales increased 38 percent
compared to the corresponding prior year quarter.  Catalyst,
performance and lab chemicals sales increased 75 percent for the
quarter.  Results benefited from the acquisition of J.T. Baker
Inc. and the reclassification of a small specialty chemical business
to continuing operations, both occurring in 1995.  Pharmaceutical 
specialties sales improved by 2 percent for the quarter.  Continued 
strength in worldwide sales volume for medicinal narcotics was the
main contributor to the increase.


MALLINCKRODT MEDICAL
Net Sales                                       Three Months Ended
(In millions)                                      September 30,
                                                ------------------
                                                 1995        1994
                                                ------      ------
Imaging                                         $ 161       $ 160
Anesthesiology & Critical Care                     77          70
                                                ------      ------
                                                $ 238       $ 230
                                                ======      ======

Mallinckrodt Medical's operating earnings for the quarter increased
to $57.8 million, up 14 percent compared to the first quarter 
of last year.  Net sales for the first quarter improved 4 percent 
over the prior year first quarter.  Imaging sales for the quarter were
1 percent higher than the corresponding prior year quarter.  Improved 
nuclear medicine sales volumes were partially offset by lower growth 
in X-ray contrast media sales, principally from timing of orders and 
distributor inventory adjustments.  Anesthesiology and critical care 
sales were up 10 percent largely from improved sales volumes of 
respiratory therapy products.


MALLINCKRODT VETERINARY
Net Sales                                       Three Months Ended
(In millions)                                      September 30,
                                                ------------------
                                                 1995        1994
                                                ------      ------    
Animal Health                                   $ 101       $ 108
                                                ======      ======

Mallinckrodt Veterinary's first quarter operating earnings were $5.0
million, up 19 percent compared to the same period last year,
excluding feed ingredients for both current and prior year.  Net sales 
on the same basis decreased 7 percent compared to the corresponding 
prior year quarter.  Lower first quarter sales resulted from the exit 
of certain Latin American distributorships last fiscal year and lower 
animal productivity sales attributable to weather conditions in North 
America.  Lower operating expenses contributed to the improvement in 
operating earniangs.

Corporate Matters
-----------------
Corporate expense increased $.7 million for the first quarter compared
to last year.  The Company's effective tax rate for the first three
months was 37.5 percent, compared to last year's 38.0 percent.  This
decrease reflects an earnings mix toward lower statutory tax rate
jurisdictions and the utilization of certain operating losses.


FINANCIAL CONDITION

The Company's financial resources are expected to continue to be
adequate to support existing businesses and fund new opportunities. 
Since June 30, 1995, cash and cash equivalents increased $28 million. 
Operations provided $23 million of cash, while acquisition and
capital spending totaled $39 million.  The Company's current ratio at
September 30, 1995, was 1.3:1.  Debt as a percentage of invested
capital was 39 percent.

The Company's Board of Directors previously authorized repurchase of a
total of 42 million shares of its common stock.  Thirty million shares
have been repurchased under this authorization, .5 million during the
quarter ended September 30, 1995.

On April 8, 1992, a shelf registration statement was filed with the
Securities and Exchange Commission (SEC) for $250 million of debt
securities.  As of September 30, 1995, $50 million of securities under
the shelf remain unissued.  On February 15, 1995, a shelf registration
statement was filed with the SEC for $250 million of debt securities. 
On September 15, 1995, the Company issued $100 million of 6.75% notes
due September 15, 2005, from this shelf registration.  As of September
30, 1995, $150 million of securities under the shelf remain unissued.

The Company has a $450 million private-placement commercial paper
program.  This program is backed by $650 million of U.S. lines of
credit, $100 million available until March 1996 and $550 million
available until November 1999.  At September 30, 1995, commercial
paper borrowings and borrowings under the U.S. credit lines amounted
to $126 million and $90 million, respectively.  At September 30, 1995,
non-U.S. lines of credit totaling $280 million were also available and
borrowings under these lines amounted to $38 million.  The non-
U.S. lines are cancelable at any time.

Estimated capital spending for the year ending June 30, 1996, is
approximately $200 million.



                      * * * * * * * * * * * * * *

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.



     Mallinckrodt Group Inc.
------------------------------
         Registrant




By:     MICHAEL A. ROCCA              By:    WILLIAM B. STONE
   ---------------------------           ------------------------
        Michael A. Rocca                     William B. Stone
      Senior Vice President                 Vice President and  
   and Chief Financial Officer                  Controller
   


Date:  November 15, 1995